Caliway CBL-514 FDA clearance and Phase 3 enrollment
Analysis based on 7 articles · First reported Jul 20, 2026 · Last updated Aug 26, 2026
The FDA clearance and Phase 3 initiation are positive catalysts for Caliway, likely boosting investor confidence and its stock price on the Taiwan Stock Exchange. The combination with Eli Lilly's tirzepatide could expand the weight management market, potentially benefiting both companies and the broader obesity treatment sector.
SK Biopharmaceuticals announced two major clinical milestones for its lead drug candidate CBL-514. The U.S. FDA cleared the Investigational New Drug application for CBL-0201WR, a Phase 2 trial combining CBL-514 with Eli Lilly's tirzepatide (Zepbound) to reduce abdominal subcutaneous fat in overweight or obese adults, targeting weight regain and stubborn fat after GLP-1 treatment. Concurrently, the pivotal Phase 3 trial SUPREME-01, evaluating CBL-514 for large-area abdominal fat reduction, received IRB approval and initiated enrollment in the U.S. Additionally, data on CBL-514's visceral fat reduction was selected for an oral presentation at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in September 2026. CBL-514 is a first-in-class small-molecule injection that selectively induces adipocyte apoptosis, potentially offering a non-surgical alternative for fat reduction. These developments mark CBL-514's expansion into the post-weight management market and could position it as the world's first non-surgical drug for large-area fat reduction if SUPREME-01 succeeds.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard